The Food and Drug Administration (FDA) submitted a report to Congress providing an update on the agency’s evaluation of potential regulatory pathways for CBD products, as well as a description of how FDA expects to proceed moving forward. However, the report indicates that little actual progress has been made. The most significant development is that FDA is considering developing a risk-based enforcement policy that could possibly clarify FDA’s enforcement priorities.
Read more from Covington.
